Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients

Oncology (Switzerland)

Volumn 84, Issue 2, 2012, Pages 115-122

  Porta, Camillo ^a,b   Paglino, Chiara ^a,b   Imarisio, Ilaria ^a,b   Ganini, Carlo ^a   Sacchi, Lucia ^c   Quaglini, Silvana ^c   Giunta, Vania ^a   De Amici, Mara ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Italian Nephro Oncology Group (GION)   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Basic fibroblast growth factor; Hepatocyte growth factor; Interleukin 6; Kidney cancer; Progression; Sunitinib

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; SCATTER FACTOR; SUNITINIB; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ASSAY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PYRROLES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868712956     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342099     Document Type: Article

References (22)

1. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221:125-138.
2. Escudier B, Albiges L: Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 2011; 71: 1179-1191.
3. Rini BI, Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
4. Zagzag D, Krishnamachary B, Yee H, et al: Stromal cell derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hip-pel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178-6188.
5. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angio-genic therapy. Int Immunopharmacol 2011; 11: 856-861.
6. Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
7. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J: Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007; 170: 1-15.
8. Hammers HJ, Verheul HM, Salumbides B, et al: Reversible epithelial to mesenchymal transition and acquired resistance to suni-tinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010; 9: 1525-1535.
9. Huang D, Ding Y, Zhou M, et al: Interleu-kin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70:1063-1071.
10. Lieu C, Heymach J, Overman M, Tran H, Kopet z S: Beyond V EGF: inhibition of the fi-broblast growth factor pathway and antian-giogenesis. Clin Cancer Res 2011; 17:6130-6139.
11. Welti JC, Gourlaouen M, Powles T, et al: Fi-broblast growth factor 2 regulates endothe-lial cell sensitivity to sunitinib. Oncogene 2011; 30:1183-1193.
12. Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-4665.
13. Banumathy G, Cairns P: Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010; 10:658-664.
14. Gore ME, Szczylik C, Porta C, Bracarda S, et al: Safety and efficacy of sunitinib for meta-static renal cell carcinoma: an expanded-ac-cess trial. La ncet Oncol 2009; 10: 757-763.
15. Sarker D, Molife R, Evans TR, et al: A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008; 14:2075-2081.
16. Rimassa L, Porta C, Borbath I, et al: Tivan-tinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT) (abstract). J Clin Oncol 2012; 30:4006.
17. Choueiri TK, Kumar Pal S, McDermott D, et al: Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC) (abstract). J Clin Oncol 2012; 30:4504.
18. Rossi JF, Négrier S, James ND, et al: A phase I/II study of siltuximab (CNTO 328), an anti-interleukin6 monoclonal antibody, in meta-static renal cell cancer. Br J Cancer 2010; 103: 1154-1162.
19. Porta C, Pedrazzoli P, Paglino C: Isimmuno-therapy re-entering the kidney cancer arena from the back door? Considerations from the phase I/II study of siltuximab. Immunother-apy 2011; 3:487-490.
20. Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28:453-459.
21. Casanovas O, Hicklin DJ, Bergers G, Hana-han D: Drug resistance by evasion of antian-giogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8:299-309.
22. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G: Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000; 60: 7163-7169.